28 Large Cap Stocks Hit 52-Week Highs On Friday
Giants of finance and pharma are hitting new peaks, but not all highs are created equal.
JPMorgan Chase (JPM), with a market value of about $959.4 billion, is the largest of 28 Large Cap stocks reaching a 52-week high on Friday. The list also includes giants like Bank of America (BAC), and together these names are hitting new peaks while the S&P 500 has returned just +0.8% over the last month. This raises a critical question for any investor: does the underlying business performance justify the price?
Here are the names at their strongest price of the past year.
The Ten Largest At New Highs
The table below shows the 10 largest of the 28 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| JPM | $959.4 Bil | 0.9% | 3.6% | 6.4% | 21.3% |
| ABBV | $459.1 Bil | 0.9% | 1.9% | 11.2% | 40.3% |
| BAC | $450.2 Bil | 1.3% | 1.3% | 7.5% | 31.7% |
| CBC | $385.0 Bil | 1.0% | 1.1% | 8.8% | 76.9% |
| MRK | $324.0 Bil | 0.5% | 2.8% | 8.7% | 61.3% |
| RTX | $286.8 Bil | 1.7% | 10.0% | 15.0% | 38.1% |
| UNP | $182.2 Bil | 1.0% | 1.8% | 18.2% | 36.1% |
| WELL | $176.4 Bil | 2.0% | 3.6% | 13.8% | 58.4% |
| BMY | $126.5 Bil | 0.9% | 2.2% | 14.2% | 32.9% |
| HWM | $116.0 Bil | 0.8% | 6.2% | 4.8% | 55.5% |
AbbVie’s valuation stands apart from its peers.
AbbVie (ABBV) has gained 11.2% over the last month, but its price reflects a steep valuation. The stock trades at 126.3 times trailing earnings. For comparison, JPMorgan Chase (JPM) is at 16.3 times and Bank of America (BAC) is at 14.2 times. AbbVie’s business is growing, with revenue up 9.5% over the last twelve months and an operating margin of 33.2%, but the multiple is an outlier on today’s list.
A 52-week high is a starting point for research, not a conclusion.
A 52-week high means the stock is at its strongest price of the last year, and that strength often persists. But a high price is not a verdict. The disciplined move is to treat the list as a screen for names with positive market sentiment, and then to check whether the business itself earns the level. The price must be justified by fundamentals like revenue growth and margins.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
Chasing Highs Is A Reflex. Owning Strength Is A System
A 52-week-high list is seductive: everything on it has been going right. But buying a stock because it is at its high is buying a price, and prices revert; what persists is the quality underneath the run.
The Trefis High Quality (HQ) Portfolio is built to own that quality before and after it makes headlines: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Admire the list; own the system.